Enhanced in vitro hemostasis and reduced thrombolysis in cyclosporine-treated renal transplant recipients.
In vitro hemostatometry and assessment of thrombolysis was carried out in three groups of 72 renal transplant recipients. In one (triple, n = 21) immunosuppression was with cyclosporine, azathioprine, and prednisolone, while a second group (CsA, n = 29) received cyclosporine and prednisolone alone, and the third group (Aza, n = 22) azathioprine and prednisolone. Results were compared with those in 30 normal controls. A statistically significant increase in hemostasis compared with controls was seen in the triple group and in patients in the CsA group studied within 2 years of transplantation. Hemostasis in the Aza group did not differ from normal. All patients in this group had been transplanted more than 2 years before study. Thrombolysis times were significantly prolonged compared with controls in all three groups. Cyclosporine treatment is associated with enhanced hemostasis and reduced thrombolysis, especially during the first 2 years after renal transplantation. If these in vitro findings reflect events in vivo, this may throw light upon the pathogenesis of the obliterative arteriolopathy that is a feature of cyclosporine nephrotoxicity.
Baker
L R
LR
Department of Nephrology, St. Bartholomew's Hospital, London, England.
Tucker
B
B
Kovacs
I B
IB
D001379:Azathioprine / Q000008:administration & dosage; D003524:Cyclosporins / Q000627:therapeutic use*; D006400:Hematocrit; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D066298:In Vitro Techniques; D016030:Kidney Transplantation; D010976:Platelet Count / Q000187:drug effects; D011239:Prednisolone / Q000008:administration & dosage; D015912:Thrombolytic Therapy
D003524:Cyclosporins; D011239:Prednisolone; D001379:Azathioprine